Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVX-800
- Development stage
- Preclinical
- Lead developer
- MaveriX Oncology
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
MVX-800 is a conditionally activated small molecule drug conjugate (CA-SMDC) being developed by MaveriX Oncology for the treatment of metastatic cancers, specifically metastatic breast cancer (mBC). The platform utilizes a proprietary linker system designed to release a camptothecin analog payload—a potent topoisomerase I inhibitor—selectively within the tumor microenvironment. By restricting the release of the cytotoxic agent to the tumor site, MVX-800 aims to improve the safety profile and therapeutic window compared to traditional systemic chemotherapies. The program is currently in the IND-enabling preclinical phase.
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on MVX-800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVX-800.